A Phase 2 Study of Patritumab Deruxtecan (HER3-DXd) in People With Advanced Melanoma

Full Title

A Phase 2 Multicenter Multicohort Open-Label Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors

Purpose

In this study, researchers want to see if the drug HER3-DXd works well against advanced melanoma. HER3-DXd is called an antibody-drug conjugate (ADC). ADCs are made up of an antibody linked to a drug. The antibody binds to specific proteins on cancer cells. The linked drug enters these cells and kills them without harming other cells.

HER3-DXd targets cells with the HER3 protein, which plays a role in cancer cell growth. By destroying these cells, HER3-DXd may help slow or stop the growth of your cancer. HER3-DXd is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have inoperable or metastatic melanoma that keeps growing after treatment that included immunotherapy.
• Have recovered from the serious side effects of prior anti-cancer treatments.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information and to see if you can join this study, please call Dr. James Smithy’s office at 646-888-6782.